Know Cancer

or
forgot password

Prospective Observation Cohort Study of Malignant Lymphoma Patients


N/A
19 Years
N/A
Open (Enrolling)
Both
Lymphoma

Thank you

Trial Information

Prospective Observation Cohort Study of Malignant Lymphoma Patients


Although the cure rate of lymphoma has been increased due to the development of newer
effective drugs, a substantial portion of patients is still suffered from relapse.
Furthermore, the treatment-related morbidity is another factor which can make the treatment
outcome worse in patients with lymphoma, especially elderly patients. Thus, this study is
going to assess factors which may affect the treatment outcome and the risk of
treatment-related morbidity.

1.Biologic factors associated with the aggressiveness of lymphoma

- molecular markers in serum, cytogenetic markers 2.Factors associated with the risk of
treatment-related morbidity

- comorbidity, nutrition status, performance status, quality of life at diagnosis


Inclusion Criteria:



- Patients who were diagnosed as lymphoma

- Over 19 years old

- Patients who agreed the enrollment of study

- Informed consent for sampling

Exclusion Criteria:

•Patients who do not want to join the study

Type of Study:

Observational [Patient Registry]

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

All cause mortality

Outcome Description:

Disease and non-disease-related mortality including treatment-related death

Outcome Time Frame:

5 years

Safety Issue:

Yes

Authority:

Korea: Food and Drug Administration

Study ID:

2011-11-056

NCT ID:

NCT01877109

Start Date:

January 2012

Completion Date:

December 2014

Related Keywords:

  • Lymphoma
  • Lymphoma
  • Prognosis
  • Biomarker
  • Quality of life
  • Lymphoma

Name

Location